Lilly's Donanemab Significantly Slowed Cognitive and Functio

Nearly half of the participants on donanemab had no clinical progression at 1 year
Phase 3 trial met primary endpoint and all secondary endpoints measuring cognitive and functional... | May 3, 2023

Related Keywords

China , United States , Eli Lilly , Joe Fletcher , Prnewswire Eli Lilly , Exchange Commission , Drug Administration , Twitter , Facebook , Lilly United States , Linkedin , Instagram , Disease Rating Scale , New England Journal , Clinical Trials , Private Securities Litigation Reform Act , United States Securities , Eli Lilly And Company Stock Exchange , News , Information , Press Release , Early , Calf , F , The , Participants , N , Donanemab , Sad , O , Linical , Progression , It , , Ear , Trial , Pet , Primary , Ndpoint , End , Wall , Secondary , Endpoints , Measuring , Cognitive , Nd Lly Us5324571083 ,